Davis Polk advised the underwriters in connection with the $150 million initial public offering of 10,000,000 American Depositary Shares of BioNTech SE.
BioNTech is listed on the Nasdaq Global Select Market under the symbol “BNTX.”
Headquartered in Germany, BioNTech is a biotechnology company that focuses on developing cancer treatments that are individualized for each patient. BioNTech combines research in immunology, cutting-edge therapeutic platforms and a suite of patient profiling and bioinformatic tools to develop individualized immunotherapies for cancer as well as other diseases, addressing the unique molecular signature of each patient’s underlying disease.
J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank, SVB Leerink, Canaccord Genuity, Bryan, Garnier & Co., Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities acted as underwriters on the deal.
The Davis Polk capital markets team included partners Deanna L. Kirkpatrick (Picture) and Yasin Keshvargar and associates Yoojin L. Kim and Meaghan Kennedy. Partner Pritesh P. Shah and associates Tilak Koilvaram and Jennifer Leather provided intellectual property and technology advice. The tax team included partner David H. Schnabel and associate Summer Xia. Counsel Marcie A. Goldstein provided FINRA advice.
Involved fees earner: Marcie Goldstein – Davis Polk & Wardwell; Meaghan Kennedy – Davis Polk & Wardwell; Yasin Keshvargar – Davis Polk & Wardwell; Yoojin Kim – Davis Polk & Wardwell; Deanna Kirkpatrick – Davis Polk & Wardwell; Tilak Koilvaram – Davis Polk & Wardwell; Jennifer Leather – Davis Polk & Wardwell; David Schnabel – Davis Polk & Wardwell; Pritesh P. Shah – Davis Polk & Wardwell; Summer Xia – Davis Polk & Wardwell;
Law Firms: Davis Polk & Wardwell;
Clients: Bank of America Merrill Lynch; Berenberg Capital Markets, LLC; Bryan, Garnier & Co; Canaccord Genuity; JP Morgan; Kempen & Co; Mirae Asset Global Investments Co., Ltd.; SVB Leerink LLC; UBS Investment Bank; Wolfe Capital Markets and Advisory;